Please try another search
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
| Name | Age | Since | Title |
|---|---|---|---|
| William W. Ericson | 62 | 2004 | Independent Director |
| John F. Milligan | 60 | 2013 | Independent Chairman |
| Christian O. Henry | 53 | 2018 | President, CEO & Director |
| Lucy Shapiro | 80 | 2012 | Independent Director |
| Randall S. Livingston | 67 | 2009 | Independent Director |
| Harold Craighead | - | - | Member of the Scientific Advisory Board |
| Watt W. Webb | - | - | Member of the Scientific Advisory Board |
| Elaine R. Mardis | 60 | 2008 | Member of the Scientific Advisory Board |
| Roger D. Kornberg | 76 | - | Member of the Scientific Advisory Board |
| Harry B. Gray | - | - | Member of the Scientific Advisory Board |
| Joseph V. Bonventre | 73 | - | Member of the Scientific Advisory Board |
| Marshall L. Mohr | 67 | 2012 | Independent Director |
| Chenming C. Hu | 75 | - | Member of the Scientific Advisory Board |
| Kenneth A. Johnson | - | - | Member of the Scientific Advisory Board |
| Jay Shendure | - | 2022 | Chairman of Scientific Advisory Board |
| Hannah A. Valantine | 71 | 2021 | Independent Director |
| Kathy P. Ordonez | 72 | 2014 | Independent Director |
| Euan A. Ashley | 51 | 2022 | Member of Scientific Advisory Board |
| Olga Troyanskaya | - | 2023 | Member of Scientific Advisory Board |
| David W. Meline | 66 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
